Show simple item record

dc.creatorPapadaki M.A., Aggouraki D., Vetsika E.-K., Xenidis N., Kallergi G., Kotsakis A., Georgoulias V.en
dc.date.accessioned2023-01-31T09:42:01Z
dc.date.available2023-01-31T09:42:01Z
dc.date.issued2021
dc.identifier10.21873/ANTICANRES.14817
dc.identifier.issn02507005
dc.identifier.urihttp://hdl.handle.net/11615/77535
dc.description.abstractBackground: To investigate the correlation between circulating tumor cells (CTCs) bearing cancer stem cell (CSC) and epithelial-to-mesenchymal (EMT) phenotypes and the different immunosuppressive cells in peripheral blood of patients with metastatic breast cancer (mBC). Materials and Methods: Blood was obtained from 38 pre-treated patients with mBC before a new line of treatment. CTC detection and characterization was performed by triple immunofluorescent staining, while Myeloid-derived Suppressor Cells (MDSCs) and T regulatory cells (Tregs) were analyzed by multi-flow cytometry. Results: CTCs were detected in 16 (42.1%) of patients. Based on the co-expression of ALDH1, TWIST and CK, CTCs revealed an important heterogeneity: CTCs with a CSC/partial-EMT, CSC/Epithelial-like, non-CSC/partial-EMT and non-CSC/Epithelial-like phenotype were detected in 7 (18.4%), 7 (18.4%), 1 (1.4%) and 9 (23.7%) of patients, respectively. Immunophenotyping of MDSCs identified 2 monocytic [M-MDSCs; CD14+CD15+CD11b+CD33+HLADR- Lin- (CD14+CD15+) and CD14+CD15-CD11b+CD33+HLA-DR-Lin- (CD14+CD15-)] and one granulocytic [GMDSCs; CD14-CD15+CD11b+CD33+HLA-DR-Lin- (CD14- CD15+)] subpopulations, expressing inducible nitric oxide synthase (iNOS) and reactive oxygen species (ROS), respectively. Patients with detectable CTCs had a higher frequency of Tregs (CD3+CD4+CD25high; p=0.022) whereas a positive correlation was found between CTC counts and the percentage of Tregs (p=0.005) and CD14+CD15+M-MDSCs (p=0.024). Patients with a partial-EMT phenotype had a higher frequency of CD14+CD15+M-MDSCs (p=0.023). Patients harboring the non-CSC/epithelial-like CTC subpopulation had an increased frequency of CD14-CD15+GMDSCs (p=0.020), along with decreased levels of CD3+CD4+CD25high FoxP3+Tregs (p=0.020). Conclusion: These findings provide evidence that CTCs in ER+/HER2- mBC patients may be under the control of the immune system and various immune escape mechanisms might be involved during the different stages of their biological evolution. © 2021 International Institute of Anticancer Research. All rights reserved.en
dc.language.isoenen
dc.sourceAnticancer Researchen
dc.source.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85100683779&doi=10.21873%2fANTICANRES.14817&partnerID=40&md5=d4f3dc1c6a8f68e1f22e6e0c6de38127
dc.subjectaldehyde dehydrogenase isoenzyme 1en
dc.subjectantineoplastic agenten
dc.subjectCD11b antigenen
dc.subjectCD14 antigenen
dc.subjectCD15 antigenen
dc.subjectCD3 antigenen
dc.subjectCD33 antigenen
dc.subjectCD4 antigenen
dc.subjectepidermal growth factor receptor 2en
dc.subjectHLA DR antigenen
dc.subjectinducible nitric oxide synthaseen
dc.subjectreactive oxygen metaboliteen
dc.subjecttranscription factor Twisten
dc.subjectTwist related protein 1en
dc.subjecttumor markeren
dc.subjectadulten
dc.subjectageden
dc.subjectArticleen
dc.subjectbreast carcinomaen
dc.subjectcancer chemotherapyen
dc.subjectcancer hormone therapyen
dc.subjectCD25+ T lymphocyteen
dc.subjectCD3+ T lymphocyteen
dc.subjectCD4+ T lymphocyteen
dc.subjectcell heterogeneityen
dc.subjectcell subpopulationen
dc.subjectcirculating tumor cellen
dc.subjectclinical articleen
dc.subjectcontrolled studyen
dc.subjectepithelial mesenchymal transitionen
dc.subjectfemaleen
dc.subjectflow cytometryen
dc.subjectfluorescence activated cell sortingen
dc.subjecthumanen
dc.subjecthuman cellen
dc.subjecthuman epidermal growth factor receptor 2 negative breast canceren
dc.subjectimmunofluorescence assayen
dc.subjectimmunophenotypingen
dc.subjectlobular carcinomaen
dc.subjectmyeloid-derived suppressor cellen
dc.subjectpriority journalen
dc.subjectregulatory T lymphocyteen
dc.subjectsystemic therapyen
dc.subjectblooden
dc.subjectbreast tumoren
dc.subjectcancer stem cellen
dc.subjectcase control studyen
dc.subjectcomparative studyen
dc.subjectimmunologyen
dc.subjectmetabolismen
dc.subjectmiddle ageden
dc.subjectmyeloid-derived suppressor cellen
dc.subjectpathologyen
dc.subjectphenotypeen
dc.subjectregulatory T lymphocyteen
dc.subjecttumor embolismen
dc.subjecttumor escapeen
dc.subjectvery elderlyen
dc.subjectAdulten
dc.subjectAgeden
dc.subjectAged, 80 and overen
dc.subjectBiomarkers, Tumoren
dc.subjectBreast Neoplasmsen
dc.subjectCase-Control Studiesen
dc.subjectEpithelial-Mesenchymal Transitionen
dc.subjectFemaleen
dc.subjectFlow Cytometryen
dc.subjectHumansen
dc.subjectImmunophenotypingen
dc.subjectMiddle Ageden
dc.subjectMyeloid-Derived Suppressor Cellsen
dc.subjectNeoplastic Cells, Circulatingen
dc.subjectNeoplastic Stem Cellsen
dc.subjectPhenotypeen
dc.subjectT-Lymphocytes, Regulatoryen
dc.subjectTumor Escapeen
dc.subjectInternational Institute of Anticancer Researchen
dc.titleEpithelial-to-mesenchymal transition heterogeneity of circulating tumor cells and their correlation with mdscs and tregs in HER2-negative metastatic breast cancer patientsen
dc.typejournalArticleen


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record